In the past few days, the 2023 performance reports of a number of listed Xiamen enterprises have been released, and Tebao Biological, Sanda Film, and Realt have achieved contrarian growth.
From the perspective of growth rate, the most eye-catching is Tebao Biotechnology, with a net profit growth of 9314% to 5$5.4 billion; The total operating income was 2.1 billion yuan, a year-on-year increase of 3755%。Behind the brilliant performance, it may be inseparable from the contribution of Peijin, another fist product that was officially approved for marketing in June last year. This product is a long-acting human granulocyte-stimulating factor product developed by Tebao Biotech after 15 years, and it is the only long-acting RRHG-CSF modified with 40kD double-stranded Y-type PEG (polyethylene glycol) in the world. The product structure patent has been authorized by many countries such as China, the United States, Europe, and Japan, and is a major national special achievement in new drug creation science and technology, and has been approved as a first-class biological product.
Since its establishment, Tebao Biotech has been engaged in the research and development, production and sales of recombinant proteins and their long-acting modified drugs, and continues to focus on research in immunology and metabolism-related fields, taking the research and development of innovative drugs as its core competitiveness.
The reporter learned from Ruierte's performance express report that in 2023, the company will achieve a total operating income of about 217.9 billion yuan, a year-on-year increase of 1122%；The net profit attributable to shareholders of the listed company was about 22.2 billion yuan, a year-on-year increase of 524%。Realt mentioned in the express report that last year, the company vigorously promoted the domestic market expansion of its own brand, and effectively made up for the impact of the decline in overseas orders on its business through refined market strategies and product innovation, ensuring the steady growth of the company's overall revenue.
According to the 2023 annual performance express report released by Sanda Film, the total operating income is 145 billion yuan, a year-on-year increase of 1517%;Net profit attributable to shareholders of listed companies25.5 billion yuan, a year-on-year increase of 1689%。
In addition, Ed Biotech and Gold Kitchen Cabinet also achieved contrarian growth last year. The data shows that in recent years, the performance of Eddid Biotech has continued to maintain double-digit steady growth, and it is recognized as a leader in the field of precision medicine at home and abroad.
Xiamen ** reporter Li Xiaoping).